This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser.
Print Document
View Excel Document
Cover
Document and Entity Information
Financial Statements
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS (Parenthetical)
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
CONSOLIDATED STATEMENTS OF CASH FLOWS
Notes to Financial Statements
Nature of Business and Plan of Operations
Summary of Significant Accounting Policies
Agreements
Convertible 4.5% Senior Notes
Liability Related to Sale of Future Royalties
Income Taxes
Capital Stock
Restructuring Charge
Commitments and Contingencies
Accounting Policies
Summary of Significant Accounting Policies (Policies)
Notes Tables
Summary of Significant Accounting Policies (Tables)
Liability Related to Sale of Future Royalties (Tables)
Commitments and Contingencies (Tables)
Notes Details
Nature of Business and Plan of Operations (Details)
Summary of Significant Accounting Policies - Subsequent Event (Details)
Summary of Significant Accounting Policies - Impact of Adopting ASC 606, Balance Sheet Adjustments (Details)
Summary of Significant Accounting Policies - Impact of Adopting ASC 606, Balance Sheet Pro-Forma Amounts (Details)
Summary of Significant Accounting Policies - Impact of Adopting ASC 606, Statement of Operations Pro-Forma Amounts (Details)
Summary of Significant Accounting Policies - Revenue Recognition (Details)
Summary of Significant Accounting Policies - Performance Obligations (Details)
Summary of Significant Accounting Policies - Contract Balances (Details)
Summary of Significant Accounting Policies - Financial Instruments (Details)
Summary of Significant Accounting Policies - Fair Value (Details)
Summary of Significant Accounting Policies - Inventory (Details)
Summary of Significant Accounting Policies - EPS and SBC (Details)
Summary of Significant Accounting Policies - Segments (Details)
Agreements - Jazz Pharmaceuticals (Details)
Agreements - Roche (Details)
Agreements - Sanofi (Details)
Agreements - CytomX (Details)
Agreements - Takeda (Details)
Agreements - Debiopharm (Details)
Convertible 4.5% Senior Notes (Details)
Liability Related to Sale of Future Royalties (Details)
Income Taxes - Deferred (Details)
Capital Stock (Details)
Restructuring Charge (Details)
Commitments and Contingencies (Details)
All Reports
Rendering Log